日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment

开发一种靶向PD-L1和PLK1的纳米颗粒免疫疗法用于肺癌治疗

Moataz Reda ,Worapol Ngamcherdtrakul ,Molly A Nelson ,Natnaree Siriwon ,Ruijie Wang ,Husam Y Zaidan ,Daniel S Bejan ,Sherif Reda ,Ngoc Ha Hoang ,Noah A Crumrine ,Justin P C Rehwaldt ,Akash Bindal ,Gordon B Mills ,Joe W Gray ,Wassana Yantasee

Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis

靶向纳米粒子联合递送 HER2 siRNA 和紫杉烷,模拟 HER2+ 乳腺癌的标准治疗:对乳腺肿瘤和脑转移的疗效

Worapol Ngamcherdtrakul, Daniel S Bejan, William Cruz-Muñoz, Moataz Reda, Husam Y Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A Nelson, Justin P C Rehwaldt, Joe W Gray, Kullervo Hynynen, Wassana Yantasee

Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform

通过抗氧化纳米粒子平台递送 PLK1 siRNA 靶向治疗转移性乳腺癌

Jingga Morry, Worapol Ngamcherdtrakul, Shenda Gu, Moataz Reda, David J Castro, Thanapon Sangvanich, Joe W Gray, Wassana Yantasee